NZ758283A - Lipid formulations for delivery of messenger rna - Google Patents
Lipid formulations for delivery of messenger rnaInfo
- Publication number
- NZ758283A NZ758283A NZ758283A NZ75828314A NZ758283A NZ 758283 A NZ758283 A NZ 758283A NZ 758283 A NZ758283 A NZ 758283A NZ 75828314 A NZ75828314 A NZ 75828314A NZ 758283 A NZ758283 A NZ 758283A
- Authority
- NZ
- New Zealand
- Prior art keywords
- delivery
- messenger rna
- lipid formulations
- mrna
- vivo
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- -1 cationic lipid Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894299P | 2013-10-22 | 2013-10-22 | |
| US201461953516P | 2014-03-14 | 2014-03-14 | |
| NZ718817A NZ718817A (en) | 2013-10-22 | 2014-10-22 | Lipid formulations for delivery of messenger rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ758283A true NZ758283A (en) | 2020-03-27 |
Family
ID=69957774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ758283A NZ758283A (en) | 2013-10-22 | 2014-10-22 | Lipid formulations for delivery of messenger rna |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ758283A (en) |
-
2014
- 2014-10-22 NZ NZ758283A patent/NZ758283A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
| EA202090919A1 (en) | Lipid Nanoparticles for the Delivery of Modified RNA Encoding VEGF-A POLYPEPTIDE | |
| TR201900649T4 (en) | Mrna therapy for the treatment of ocular diseases. | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| PH12020500336A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| PH12018502221A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| MX2022006512A (en) | Trialkyl cationic lipids and methods of use thereof. | |
| MX2014004960A (en) | Combinational liposome compositions for cancer therapy. | |
| MX2016005236A (en) | Cns delivery of mrna and uses thereof. | |
| TR201816986T4 (en) | Lipids for therapeutic agent delivery formulations. | |
| NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| NZ719345A (en) | Lipid nanoparticle compositions and methods for mrna delivery | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| WO2013084000A3 (en) | Exosomes for delivery of biotherapeutics | |
| WO2015011633A8 (en) | Compositions and methods for delivering messenger rna | |
| MY172578A (en) | Oral dosing of glp-1 compounds | |
| MX352324B (en) | Multivalent synthetic nanocarrier vaccines. | |
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| MX348823B (en) | Stable formulations of linaclotide. | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| EP2568990A4 (en) | Method of producing pleurodesis | |
| NZ758283A (en) | Lipid formulations for delivery of messenger rna | |
| MX367773B (en) | Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof. | |
| NZ745686A (en) | Lipid nanoparticle compositions and methods for mrna delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2022 BY THOMSON REUTERS Effective date: 20210902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2023 BY CPA GLOBAL Effective date: 20220909 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 OCT 2024 BY CPA GLOBAL Effective date: 20230907 |